Exane BNP Paribas Downgrades GlaxoSmithKline (GSK) to Underperform
Tweet
Share
E-mailGet Alerts GSK Hot Sheet
Price: $49.52 -0.96%
Rating Summary:
6 Buy, 16 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
6 Buy, 16 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Exane BNP Paribas downgraded GlaxoSmithKline (NYSE: GSK) from Outperform to Underperform.
For an analyst ratings summary and ratings history on GlaxoSmithKline click here. For more ratings news on GlaxoSmithKline click here.
Shares of GlaxoSmithKline closed at $47.11 yesterday.
For an analyst ratings summary and ratings history on GlaxoSmithKline click here. For more ratings news on GlaxoSmithKline click here.
Shares of GlaxoSmithKline closed at $47.11 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RBC Capital Downgrades Accelerant Holdings (ARX) to Sector Perform
- Wolfe Research Downgrades T-Mobile (TMUS) to Peerperform
- Goldman Sachs Downgrades Douglas AG (DOU:GR) to Sell
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
